These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 16511411

  • 1. Protective effects of IL4-589T and RANTES-28G on HIV-1 disease progression in infected Thai females.
    Wichukchinda N, Nakayama EE, Rojanawiwat A, Pathipvanich P, Auwanit W, Vongsheree S, Ariyoshi K, Sawanpanyalert P, Shioda T.
    AIDS; 2006 Jan 09; 20(2):189-96. PubMed ID: 16511411
    [Abstract] [Full Text] [Related]

  • 2. Association of RANTES -403 G/A, -28 C/G and In1.1 T/C polymorphism with HIV-1 transmission and progression among North Indians.
    Rathore A, Chatterjee A, Sivarama P, Yamamoto N, Singhal PK, Dhole TN.
    J Med Virol; 2008 Jul 09; 80(7):1133-41. PubMed ID: 18461620
    [Abstract] [Full Text] [Related]

  • 3. [Preliminary study on the association of chemokine RANTES gene polymorphisms with HIV-1 infection in Chinese Han population].
    Liu XL, Wang FS, Jin L, Liu MX, Xu DZ.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Nov 09; 24(11):971-5. PubMed ID: 14687494
    [Abstract] [Full Text] [Related]

  • 4. Effects of single nucleotide polymorphisms in the RANTES promoter region in healthy and HIV-infected indigenous Chinese.
    Zhao XY, Lee SS, Wong KH, Chan KC, Ma S, Yam WC, Yuen KY, Ng MH, Zheng BJ.
    Eur J Immunogenet; 2004 Aug 09; 31(4):179-83. PubMed ID: 15265023
    [Abstract] [Full Text] [Related]

  • 5. RANTES -28G delays and DC-SIGN - 139C enhances AIDS progression in HIV type 1-infected Japanese hemophiliacs.
    Koizumi Y, Kageyama S, Fujiyama Y, Miyashita M, Lwembe R, Ogino K, Shioda T, Ichimura H.
    AIDS Res Hum Retroviruses; 2007 May 09; 23(5):713-9. PubMed ID: 17530998
    [Abstract] [Full Text] [Related]

  • 6. Influence of RANTES, SDF-1 and TGF-beta levels on the value of interleukin-7 as a predictor of virological response in HIV-1-infected patients receiving double boosted protease inhibitor-based therapy.
    Boulassel MR, Smith GH, Edwardes MD, Young M, Klein M, Gilmore N, Macleod J, Leblanc R, René P, Allan J, Lalonde RG, Routy JP.
    HIV Med; 2005 Jul 09; 6(4):268-77. PubMed ID: 16011532
    [Abstract] [Full Text] [Related]

  • 7. Protective effect of interleukin-4 -589T polymorphism on human immunodeficiency virus type 1 disease progression: relationship with virus load.
    Nakayama EE, Meyer L, Iwamoto A, Persoz A, Nagai Y, Rouzioux C, Delfraissy JF, Debre P, McIlroy D, Theodorou I, Shioda T, SEROCO Study Group.
    J Infect Dis; 2002 Apr 15; 185(8):1183-6. PubMed ID: 11930331
    [Abstract] [Full Text] [Related]

  • 8. RANTES production from CD4+ lymphocytes correlates with host genotype and rates of human immunodeficiency virus type 1 disease progression.
    Paxton WA, Neumann AU, Kang S, Deutch L, Brown RC, Koup RA, Wolinsky SM.
    J Infect Dis; 2001 Jun 01; 183(11):1678-81. PubMed ID: 11343219
    [Abstract] [Full Text] [Related]

  • 9. Genetic polymorphisms in CX3CR1 predict HIV-1 disease progression in children independently of CD4+ lymphocyte count and HIV-1 RNA load.
    Singh KK, Hughes MD, Chen J, Spector SA.
    J Infect Dis; 2005 Jun 01; 191(11):1971-80. PubMed ID: 15871132
    [Abstract] [Full Text] [Related]

  • 10. Heterozygosity for a defective gene for CC chemokine receptor 5 is not the sole determinant for the immunologic and virologic phenotype of HIV-infected long-term nonprogressors.
    Cohen OJ, Vaccarezza M, Lam GK, Baird BF, Wildt K, Murphy PM, Zimmerman PA, Nutman TB, Fox CH, Hoover S, Adelsberger J, Baseler M, Arthos J, Davey RT, Dewar RL, Metcalf J, Schwartzentruber DJ, Orenstein JM, Buchbinder S, Saah AJ, Detels R, Phair J, Rinaldo C, Margolick JB, Pantaleo G, Fauci AS.
    J Clin Invest; 1997 Sep 15; 100(6):1581-9. PubMed ID: 9294127
    [Abstract] [Full Text] [Related]

  • 11. The effect of stromal cell-derived factor 1 (SDF1/CXCL12) genetic polymorphism on HIV-1 disease progression.
    Reiche EM, Ehara Watanabe MA, Bonametti AM, Kaminami Morimoto H, Akira Morimoto A, Wiechmann SL, Breganó JW, Matsuo T, Vissoci Reiche F, Miranda HC, Brajão Oliveira K, Vogler IH, Siscar AR.
    Int J Mol Med; 2006 Oct 15; 18(4):785-93. PubMed ID: 16964435
    [Abstract] [Full Text] [Related]

  • 12. Interleukin-4 promoter polymorphisms: a genetic prognostic factor for survival in metastatic renal cell carcinoma.
    Kleinrath T, Gassner C, Lackner P, Thurnher M, Ramoner R.
    J Clin Oncol; 2007 Mar 01; 25(7):845-51. PubMed ID: 17327605
    [Abstract] [Full Text] [Related]

  • 13. Reduced mortality and CD4 cell loss among carriers of the interleukin-10 -1082G allele in a Zimbabwean cohort of HIV-1-infected adults.
    Erikstrup C, Kallestrup P, Zinyama-Gutsire RB, Gomo E, Butterworth AE, Pedersen BK, Ostrowski SR, Gerstoft J, Ullum H.
    AIDS; 2007 Nov 12; 21(17):2283-91. PubMed ID: 18090276
    [Abstract] [Full Text] [Related]

  • 14. Serum levels of MIP-1beta and RANTES in HIV-1 subtype CRF01_AE infected patients with different rates of disease progression.
    Chuenchitra T, Wasi C, de Souza M, Nitayaphan S, Louisirirotchanakul S, Sutthent R, Brown AE, Birx DL, Polonis VR.
    Southeast Asian J Trop Med Public Health; 2008 Sep 12; 39(5):856-62. PubMed ID: 19058580
    [Abstract] [Full Text] [Related]

  • 15. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
    Lapadula G, Torti C, Maggiolo F, Casari S, Suter F, Minoli L, Pezzoli C, Di Pietro M, Migliorino G, Ouiros-Roldan E, Ladisa N, Sighinolfi L, Costarelli S, Carosi G, Italian MASTER Cohort.
    Antivir Ther; 2007 Sep 12; 12(6):941-7. PubMed ID: 17926648
    [Abstract] [Full Text] [Related]

  • 16. Modulating influence on HIV/AIDS by interacting RANTES gene variants.
    An P, Nelson GW, Wang L, Donfield S, Goedert JJ, Phair J, Vlahov D, Buchbinder S, Farrar WL, Modi W, O'Brien SJ, Winkler CA.
    Proc Natl Acad Sci U S A; 2002 Jul 23; 99(15):10002-7. PubMed ID: 12114533
    [Abstract] [Full Text] [Related]

  • 17. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
    Laurichesse JJ, Persoz A, Theodorou I, Rouzioux C, Delfraissy JF, Meyer L.
    HIV Med; 2007 May 23; 8(4):213-9. PubMed ID: 17461848
    [Abstract] [Full Text] [Related]

  • 18. CCL5/RANTES chemokine gene promoter polymorphisms are not associated with atopic and nonatopic asthma in a Spanish population.
    Muro M, Marín L, Torio A, Pagan JA, Alvarez-López MR.
    Int J Immunogenet; 2008 Feb 23; 35(1):19-23. PubMed ID: 18186796
    [Abstract] [Full Text] [Related]

  • 19. Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl.
    Wood E, Hogg RS, Yip B, Moore D, Harrigan PR, Montaner JS.
    AIDS; 2006 May 12; 20(8):1117-23. PubMed ID: 16691062
    [Abstract] [Full Text] [Related]

  • 20. Virologic and host characteristics of human immunodeficiency virus type 1-infected pediatric long term survivors.
    Alexander L, Cuchura L, Simpson BJ, Andiman WA.
    Pediatr Infect Dis J; 2006 Feb 12; 25(2):135-41. PubMed ID: 16462290
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.